4/15
08:00 am
incy
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
Low
Report
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
4/9
08:00 am
incy
Incyte to Report First Quarter Financial Results
Low
Report
Incyte to Report First Quarter Financial Results
4/5
01:18 am
incy
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed? [Yahoo! Finance]
4/2
06:05 pm
incy
Incyte (INCY) was upgraded by
Weiss Ratings from "hold (c+)" to "buy (b-)".
Low
Report
Incyte (INCY) was upgraded by
Weiss Ratings from "hold (c+)" to "buy (b-)".
4/1
06:24 am
incy
Stocks hedge funds love [Seeking Alpha]
Low
Report
Stocks hedge funds love [Seeking Alpha]
3/30
06:02 am
incy
A Look Back at Biotechnology Stocks' Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack [Yahoo! Finance]
Low
Report
A Look Back at Biotechnology Stocks' Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack [Yahoo! Finance]
3/28
03:07 pm
incy
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Low
Report
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
3/28
03:00 pm
incy
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
3/25
12:33 pm
incy
Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.
Low
Report
Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.
3/25
09:00 am
incy
Incyte Announces Executive Leadership Appointments
Low
Report
Incyte Announces Executive Leadership Appointments
3/25
08:03 am
incy
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
Low
Report
Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
3/24
09:02 pm
incy
Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.
Low
Report
Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.
3/22
11:12 pm
incy
Incyte: An Undervalued Healthcare Gem [Seeking Alpha]
Low
Report
Incyte: An Undervalued Healthcare Gem [Seeking Alpha]
3/20
10:00 am
incy
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
3/18
06:39 pm
incy
Incyte (INCY) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c+)".
Low
Report
Incyte (INCY) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c+)".
3/18
11:27 am
incy
Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]
Low
Report
Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]
3/17
08:57 pm
incy
Tracking Baker Brothers Portfolio - Q4 2025 Update [Seeking Alpha]
Low
Report
Tracking Baker Brothers Portfolio - Q4 2025 Update [Seeking Alpha]
3/17
10:26 am
incy
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue [Seeking Alpha]
Low
Report
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue [Seeking Alpha]
3/17
08:13 am
incy
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico [Yahoo! Finance]
Low
Report
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico [Yahoo! Finance]
3/17
07:42 am
incy
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
3/17
07:30 am
incy
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
Low
Report
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
3/16
03:56 pm
incy
Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond [Seeking Alpha]
Low
Report
Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond [Seeking Alpha]
3/16
08:43 am
incy
Incyte (INCY) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $94.00 price target on the stock.
Neutral
Report
Incyte (INCY) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $94.00 price target on the stock.
3/14
10:23 pm
incy
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer [Yahoo! Finance]
Low
Report
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer [Yahoo! Finance]
3/13
10:14 am
incy
2 Value Stocks to Consider Right Now and 1 We Ignore [Yahoo! Finance]
Low
Report
2 Value Stocks to Consider Right Now and 1 We Ignore [Yahoo! Finance]